# Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct07719894` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07719894](<https://clinicaltrials.gov/study/NCT07719894>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07719894

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT07719894. Randomized; no masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT07719894, source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)
- Started: 2026-05-06 (actual) (ClinicalTrials.gov record NCT07719894, source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07719894, source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07719894, source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07719894, source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07719894-2026-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
- Acronym: Cilo-Asa
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Atherosclerosis
- Intervention (Drug): Cilostazol
- Intervention (Drug): Aspirin
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: b17ef3cf2c15f67ac43e7499b3528957d076347d7d501921ca0573c700391d16
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
